Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2034
Description
Key Highlights
C3G presents with various glomerulonephritis patterns, including membranoproliferative, mesangial proliferative, diffuse endocapillary proliferative, and crescentic types.
C3G is an ultra-rare kidney disease with a very low global prevalence and is likely underdiagnosed. It can affect all ages but most commonly presents in children, adolescents, and young adults.
Two forms of C3G have been found through several secondary sources, namely Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN), which vary as per the patterns of damage and inflammation in the glomeruli. In addition, it is important to note that the features of DDD tend to appear earlier than those of C3GN, usually in adolescence.
C3G is associated with a challenging long-term outlook, driven by its progressive course and high risk of recurrence. Approximately 30–50% of patients develop End-stage Kidney Disease (ESKD) within 10 years of diagnosis.
The diagnosed prevalent population of C3G in the 7MM is expected to grow between 2024 and 2034, driven by advancements in complement biology and enhanced diagnostic capabilities. Greater use of genetic testing, complement assays, and renal biopsy interpretation supported by multidisciplinary collaboration is enabling earlier and more accurate diagnosis.
DelveInsight’s “Complement 3 Glomerulopathy – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Complement 3 Glomerulopathy, historical and forecasted epidemiology of Complement 3 Glomerulopathy in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Complement 3 Glomerulopathy Disease Understanding
Complement 3 Glomerulopathy Overview
The term complement 3 glomerulopathy was adopted by expert consensus in 2013 to define a group of rare kidney diseases driven by dysregulation of the complement cascade. The major features of Complement 3 Glomerulopathy include high levels of protein in the urine (proteinuria), blood in the urine (hematuria), reduced amounts of urine, low levels of protein in the blood, and swelling in several areas of the body.
Complement 3 Glomerulopathy is a type of glomerular disease, characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a significant amount of immunoglobulin and without deposition of C1q and C4. The accumulation of C3 without a significant amount of classical or lectin complement components in the glomeruli suggests dysregulation of the alternative complement pathway as the underlying pathogenetic mechanism. This finding, in the absence or near absence of immunoglobulin deposits in a patient with the classic clinical features of glomerulonephritis, is the single diagnostic criterion. The rarity of Complement 3 Glomerulopathy makes it challenging to derive precise incidence and prevalence of the indication; however, several small cohort studies have generated estimates of limited reliability.
Complement 3 Glomerulopathy Diagnosis
In most cases, diagnosis of Complement 3 Glomerulopathy requires a renal biopsy and careful review of light microscopy, immunofluorescence, and electron microscopy. Broadly, Complement 3 Glomerulopathy is defined as the predominant staining of C3 on immunofluorescence (IF) when compared to immunoglobulin (intensity >2 orders of magnitude). Complement 3 Glomerulopathy is classified by electron microscopy findings into DDD or C3GN, depending on the presence or absence of dense osmiophilic intramembranous deposits. However, the various diagnostic tests used for establishing a Complement 3 Glomerulopathy diagnosis are as follows: Urine test, Blood test, Glomerular filtration rate (GFR), and Kidney biopsy.
Complement 3 Glomerulopathy Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent population of Complement 3 Glomerulopathy, type-specific diagnosed prevalent population of Complement 3 Glomerulopathy, age-specific diagnosed prevalent population of Complement 3 Glomerulopathy, and total treated cases of Complement 3 Glomerulopathy in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan from 2020 to 2034.
In 2024, the diagnosed prevalent population of C3 glomerulopathy in the 7MM was approximately 5,800. This number is expected to rise through 2034, driven by advances in complement biology, improved diagnostics, and wider use of genetic testing, complement assays, and multidisciplinary biopsy evaluation.
The diagnosed prevalent population of Complement 3 Glomerulopathy, in the United States, was found to be 3,400 in 2024.
In 2024, Complement 3 Glomerulopathy predominantly affected adults in the United States, with 89% of the cases, while the pediatric population accounted for the remaining 11%. By 2034, these numbers are expected to rise to 3,800 cases in adults and 480 cases in children.
In Japan, adults are more prevalent in Complement 3 Glomerulopathy compared to pediatrics.
Scope of the Report
The report covers a segment of key events, an executive summary, descriptive overview of Complement 3 Glomerulopathy, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
A detailed review of the Complement 3 Glomerulopathy epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
Complement 3 Glomerulopathy Report Insights
Patient Population
Patient population by gender and age
Country-wise Epidemiology Distribution
Report Key Strengths
10 Years Forecast
The 7MM Coverage
Complement 3 Glomerulopathy Epidemiology Segmentation
Complement 3 Glomerulopathy Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
What are the disease risks and burdens of complement 3 glomerulopathy epidemiology? What will be the growth opportunities across the 7MM with respect to the patient population about complement 3 glomerulopathy epidemiology?
What is the historical and forecasted to complement 3 glomerulopathy epidemiology patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Which age group is the largest contributor to patients affected with complement 3 glomerulopathy epidemiology?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.
C3G presents with various glomerulonephritis patterns, including membranoproliferative, mesangial proliferative, diffuse endocapillary proliferative, and crescentic types.
C3G is an ultra-rare kidney disease with a very low global prevalence and is likely underdiagnosed. It can affect all ages but most commonly presents in children, adolescents, and young adults.
Two forms of C3G have been found through several secondary sources, namely Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN), which vary as per the patterns of damage and inflammation in the glomeruli. In addition, it is important to note that the features of DDD tend to appear earlier than those of C3GN, usually in adolescence.
C3G is associated with a challenging long-term outlook, driven by its progressive course and high risk of recurrence. Approximately 30–50% of patients develop End-stage Kidney Disease (ESKD) within 10 years of diagnosis.
The diagnosed prevalent population of C3G in the 7MM is expected to grow between 2024 and 2034, driven by advancements in complement biology and enhanced diagnostic capabilities. Greater use of genetic testing, complement assays, and renal biopsy interpretation supported by multidisciplinary collaboration is enabling earlier and more accurate diagnosis.
DelveInsight’s “Complement 3 Glomerulopathy – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Complement 3 Glomerulopathy, historical and forecasted epidemiology of Complement 3 Glomerulopathy in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Complement 3 Glomerulopathy Disease Understanding
Complement 3 Glomerulopathy Overview
The term complement 3 glomerulopathy was adopted by expert consensus in 2013 to define a group of rare kidney diseases driven by dysregulation of the complement cascade. The major features of Complement 3 Glomerulopathy include high levels of protein in the urine (proteinuria), blood in the urine (hematuria), reduced amounts of urine, low levels of protein in the blood, and swelling in several areas of the body.
Complement 3 Glomerulopathy is a type of glomerular disease, characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a significant amount of immunoglobulin and without deposition of C1q and C4. The accumulation of C3 without a significant amount of classical or lectin complement components in the glomeruli suggests dysregulation of the alternative complement pathway as the underlying pathogenetic mechanism. This finding, in the absence or near absence of immunoglobulin deposits in a patient with the classic clinical features of glomerulonephritis, is the single diagnostic criterion. The rarity of Complement 3 Glomerulopathy makes it challenging to derive precise incidence and prevalence of the indication; however, several small cohort studies have generated estimates of limited reliability.
Complement 3 Glomerulopathy Diagnosis
In most cases, diagnosis of Complement 3 Glomerulopathy requires a renal biopsy and careful review of light microscopy, immunofluorescence, and electron microscopy. Broadly, Complement 3 Glomerulopathy is defined as the predominant staining of C3 on immunofluorescence (IF) when compared to immunoglobulin (intensity >2 orders of magnitude). Complement 3 Glomerulopathy is classified by electron microscopy findings into DDD or C3GN, depending on the presence or absence of dense osmiophilic intramembranous deposits. However, the various diagnostic tests used for establishing a Complement 3 Glomerulopathy diagnosis are as follows: Urine test, Blood test, Glomerular filtration rate (GFR), and Kidney biopsy.
Complement 3 Glomerulopathy Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent population of Complement 3 Glomerulopathy, type-specific diagnosed prevalent population of Complement 3 Glomerulopathy, age-specific diagnosed prevalent population of Complement 3 Glomerulopathy, and total treated cases of Complement 3 Glomerulopathy in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan from 2020 to 2034.
In 2024, the diagnosed prevalent population of C3 glomerulopathy in the 7MM was approximately 5,800. This number is expected to rise through 2034, driven by advances in complement biology, improved diagnostics, and wider use of genetic testing, complement assays, and multidisciplinary biopsy evaluation.
The diagnosed prevalent population of Complement 3 Glomerulopathy, in the United States, was found to be 3,400 in 2024.
In 2024, Complement 3 Glomerulopathy predominantly affected adults in the United States, with 89% of the cases, while the pediatric population accounted for the remaining 11%. By 2034, these numbers are expected to rise to 3,800 cases in adults and 480 cases in children.
In Japan, adults are more prevalent in Complement 3 Glomerulopathy compared to pediatrics.
Scope of the Report
The report covers a segment of key events, an executive summary, descriptive overview of Complement 3 Glomerulopathy, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
A detailed review of the Complement 3 Glomerulopathy epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
Complement 3 Glomerulopathy Report Insights
Patient Population
Patient population by gender and age
Country-wise Epidemiology Distribution
Report Key Strengths
10 Years Forecast
The 7MM Coverage
Complement 3 Glomerulopathy Epidemiology Segmentation
Complement 3 Glomerulopathy Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
What are the disease risks and burdens of complement 3 glomerulopathy epidemiology? What will be the growth opportunities across the 7MM with respect to the patient population about complement 3 glomerulopathy epidemiology?
What is the historical and forecasted to complement 3 glomerulopathy epidemiology patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Which age group is the largest contributor to patients affected with complement 3 glomerulopathy epidemiology?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary of C3G
- 4. Epidemiology Forecast Methodology
- 5. Disease Background and Overview
- 5.1. Introduction
- 5.2. Familiar Forms of C3G
- 5.3. Causes and Risk Factors
- 5.4. Symptoms
- 5.5. Pathophysiology
- 5.6. Pathogenesis
- 5.7. Diagnosis
- 5.8. Differential Diagnosis
- 6. Epidemiology and Patient Population
- 6.1. Key Findings
- 6.2. Assumptions and Rationales
- 6.3. Total Diagnosed Prevalent Population of C3G in the 7MM
- 6.4. The United States
- 6.4.1. Total Diagnosed Prevalent Population of C3G in the United States
- 6.4.2. Type-specific Diagnosed Prevalent Population of C3G in the United States
- 6.4.3. Age-specific Diagnosed Prevalent Population of C3G in the United States
- 6.4.4. Total Treated Cases of C3G in the United States
- 6.5. EU4 and the UK
- 6.5.1. Total Diagnosed Prevalent Population of C3G in EU4 and the UK
- 6.5.2. Type-specific Diagnosed Prevalent Population of C3G in EU4 and the UK
- 6.5.3. Age-specific Diagnosed Prevalent Population of C3G in the EU4 and the UK
- 6.5.4. Total Treated Cases of C3G in EU4 and the UK
- 6.6. Japan
- 6.6.1. Total Diagnosed Prevalent Population of C3G in Japan
- 6.6.2. Type-specific Diagnosed Prevalent Population of C3G in Japan
- 6.6.3. Age-specific Diagnosed Prevalent Population of C3G in Japan
- 6.6.4. Total Treated Cases of C3G in Japan
- 7. Appendix
- 7.1. Bibliography
- 7.2. Report Methodology
- 8. DelveInsight Capabilities
- 9. Disclaimer
- 10. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
